SAR-443809
Based on 1 Customer Validation
SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity.
For research use only. We do not sell to patients.
- Purity : 97.06%
- Molecular Weight:144.13 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
SAR-443809 (Human FB: 6-500 nM; human FBb: 0.4-30 nM; SAR443809 Fab: 3.7-300 nM; 25°C during assay) binds with high affinity to human factor Bb (KD = 7.3 nM) and cynomolgus factor Bb (KD = 61 nM), and its Fab fragment binds to the active alternative pathway C3 convertase (C3bBb) with high affinity (KD = 0.5 nM)[1].
SAR-443809 (50 minutes at 37°C) inhibits alternative pathway-mediated hemolysis of rabbit erythrocytes with an IC50 of 28.45 μg/mL[1].
SAR-443809 (50 minutes at 37°C) inhibits alternative pathway-mediated C3b deposition on rabbit erythrocytes with an apparent IC50 of 33.8 μg/mL[1].
SAR-443809 potently and selectively inhibits the human complement alternative pathway (IC50 = 8.47 μg/mL) and cynomolgus monkey complement alternative pathway (IC50 = 15.72 μg/mL) by blocking cleavage of C3 and factor B, without inhibiting the classical or lectin pathways[1].
SAR-443809 selectively binds to human factor Bb (EC50 = 30.9 ng/mL) and shows no specific binding to other tested plasma serine proteases, including most complement system enzymes[1].
SAR-443809 (100 μg/mL; 30 minutes at 37°C) inhibits unregulated fluid-phase C3 cleavage in factor H-depleted human serum, preventing consumption of C3 via alternative pathway tickover[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys (female)[1]
-
Dosage:15 mg/kg (i.v.); 15 mg/kg (s.c.)
-
Administration:i.v.; single dose
s.c.; single dose -
Result:Achieved 90% inhibition of alternative pathway complement activity at 24 hours post-dose, sustained for at least 288 hours (i.v.).
Reached 90% inhibition of alternative pathway complement activity between 24-48 hours post-dose, sustained for at least 288 hours (s.c.).
Showed no classical pathway inhibition.
Gene ID
Accession
AAH04143.1
Target
Complement Factor B/CFB
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded SAR-443809 on biosensor, can bind Complement Factor B/CFB Protein, Human (HEK293, HY-P7813) with an affinity constant of 1.18E-08 M as determined in BLI assay.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 144.13 kDa
-
Color Colorless to light yellow
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)